insulin dose at GLP-1RA initiation was only decreased if HbA1c was below 7.5% ( Our current practice is to consider a ~20% bolus insulin decrease and a ~10% basal insulin decrease before GLP-1RA initiation, although prior A1c, risk of hypoglycemia, potential risk of ketosis due to reduced insulin doses, as well as other patient-specific factors should guide the final insulin dose changes
This effect is more pronounced with short-acting GLP-1 agents and tends to diminish over time with long-acting formulations
Semaglutide Tablets (Rybelsus) Currently, the primary oral semaglutide tablet available in the UK is branded as Rybelsus
Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, et al
Tobaiqy, M
The packaging is simple yet functional, keeping the capsules fresh